Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2014

View Archived Issues

Chinese team divulges novel BTK inhibitors

AstraZeneca and Max Planck Institute to create CVMD chemistry unit

Cynapsus Therapeutics receives grant and plans phase II study of sublingual apomorphine

Otonomy releases phase III data for AuriPro in middle ear effusion

Peroxynitrite decomposing catalyst has antidiabetic effects

Researchers present results for BP-C1 in patients with stage IV breast cancer

Phase III results for trelagliptin, an oral, once-weekly DPP IV inhibitor

LAPS-CA-Exendin 4 designed for patients with type 2 diabetes

Novel SYK inhibitors described by Merck & Co.

Actelion Pharmaceuticals prepares new P2X7 antagonists

Researchers at Pfizer disclose novel BACE inhibitors

New MAbs for influenza A virus patented by Belgian researchers

U.S. researchers design new series of protein kinase inhibitors for cancer

Researchers present phase I results for LGD-6972

A1M Pharma pre-eclampsia therapy receives European orphan drug designation

Celgene reports data from phase III POSTURE study

La Jolla Pharmaceutical to conduct phase III registration program for LJPC-501

Salix Pharmaceuticals to merge with Cosmo Technologies

Akashi Therapeutics presents data on HT-100 in Duchenne muscular dystrophy

Sunesis Pharmaceuticals receives positive opinion on pediatric investigation plan for vosaroxin

Vaccine for ricin and anthrax achieves simultaneous protection milestone

Valeant Pharmaceuticals acquires PreCision Dermatology

FDA places clinical hold on Revolixys Kit phase III trial

Nuvilex completes preparations for preclinical studies of encapsulated cells in ascites

Astellas files NDA for isavuconazole in invasive fungal infections

AbbVie makes revised conditional non-binding proposal offer to Shire

Humanetics awarded NCI grant to test BIO-300 for radiation-induced erectile dysfunction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...